ZFSW
Cancer vaccine developer
ZFSW, founded in July, 1995 and headquartered in Chongqing, is an anti-cancer vaccine developer. The founder is Jiang Rensheng. Listed on the SZSE on September 28, 2010, the company's major shareholders are Jiang Rensheng, Jiang Lingfeng and Wu Guanjiang. Rivals that have direct and indirect competition with ZFSW include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
20 Chinese Companies to Watch in Q1 2023– Healthcare+
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.
Apr 07, 2023 01:39 PM
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
China VC Investment List Q4 2022 – Healthcare
For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.
Jan 05, 2023 06:55 PM
15 Companies to Watch in December 2022 — Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds and industry events that took place in China's healthcare space in December 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.
Jan 04, 2023 05:28 PM
2022 China Year-in-Review | Healthcare
2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the second part, we will list major M&A, product approvals, and strategic collaboration news. It's by no means exhaustive, but it'll shed some light on what's to come
Dec 23, 2022 10:40 AM
2022 China Year-in-Review | Healthcare
2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the first part, we will list major financing and IPO news. It's by no means exhaustive, but it'll shed some light on what's to come.
Dec 21, 2022 07:02 PM
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM
EqualOcean 2022 China AI Health 30 Companies list Reveals
Starting from September 2022, EqualOcean had been conducting deep market research and expert interviews aiming to select out 30 most representative China-based companies in the AI Health sector that are with the most growth and development potential. It is finally officially finalized, and we give our deep and sincere congratulations to those 30 companies and wish them all the best in the future.
Nov 09, 2022 01:00 AM
Dissection of Applications of AI in China’s Healthcare Industry
As AI enables automatic problem-solving and is highly intelligence, it can be applied to a wide variety of fields in the healthcare, especially for the labour intensive tasks. In China, from the basic medical health records to the complex disease treatment planning and prediction, you can always find the involvement of AI. Here, we choose seven sectors with more mature development and introduced them.
Oct 30, 2022 01:54 PM
China's Road to Tackle Autoimmune Diseases Globally
The market of autoimmune diseases medication is vast both in China and overseas and presents great opportunities. However, the number of Chinese players specializing in autoimmune diseases is limited. This article introduced the autoimmune diseases medication market in China and explained why Chinese players are limited then give some recommendations on what efforts Chinese companies can make to compete with western players.
Oct 10, 2022 03:55 PM
China VC Investment List Q3 2022 – Healthcare
This is part of a seven-part series on China's VC investment in Q3 2022. This series features firms spanning seven industries, including automaking, healthcare, new consumption, intelligent hardware, smart manufacturing, enterprise services and emerging technologies.
Oct 08, 2022 02:32 PM
Blood Cancer, ‘Bloody Invisible Invader’ in China
Blood cancers including leukemia, lymphoma and myeloma are the top 10 cancer diseases worldwide. However, due to their distinct features from solid cancers, the diagnosis of them is much more challenging and requires extra care. Patients possessing blood cancers often have less awareness and blood cancers can be a so-called the invisible invader. This article gives an introduction to blood cancers then generally dissects what challenges the industry is facing in China.
Sep 22, 2022 11:09 AM
15 Companies to Watch in August 2022- Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in August 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.
Sep 02, 2022 10:20 AM
Analysis of In Vitro Diagnostics Industry in China
It has been almost three years since the coronavirus outbreak. In the post-Covid era, PCR tests and antigen reagents have become part of daily essentials. The increasing demand for PCR tests drives the development of IVD in China. What is IVD? How to explain its popularity in China over the past two or three years? You will find all the answers above in this article.
Aug 23, 2022 12:15 PM
What Waits Ahead for China’s Healthcare Innovation and its Globalization?
China has been of great interest to global healthcare investors and organizations. This month, we featured four guest speakers from different industry groups under heathcare to share their thoughts on China’s healthcare innovation and globalization.
Aug 21, 2022 10:21 AM
15 Companies to Watch in July 2022 - Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in July 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.
Aug 11, 2022 09:58 AM